Main Article Content
Abstract
Epirubicin(10-(4-amino-5-hydroxy-6-methyl-oxan-2-yl)oxy-6,8,11-trihydroxy-8-(2hydroxyacetyl)-1-methoxy-9,10-dihydro-7H-tetracene-5,12-dione) is an anthracycline anticancer agent used to treat node-positive breast cancer, ovarian cancer, gastric cancer, lung cancer, and lymphomas (Neil,2006). Streptomyces peucetius strains produce epirubicin through chemical transformation. It interferes with DNA and RNA production by creating a compound and intercalating into nucleotide base pairs. It is preferred over doxorubicin due to its lower toxicity at equimolar dose. This may be due to the opposite chirality caused by the hydroxyl group at the 4' carbon of the sugar moiety, resulting in faster elimination and less toxicity. Docetaxel is a toxoid medication with anti-cancer effects. The semi-synthetic procedure begins with a precursor derived from regenerated yew needles. Docetaxel is available in two forms: anhydrous and trihydrate. Aventis Pharmaceuticals developed Docetaxel, popularly known as Taxotere, to treat a specific kind of cancer. The medication is currently authorised in 90 nations for treating advanced lung cancer and 70 countries for treating advanced non-small cell lung cancer.